Oral Dermatitis Treatments Have Been Developed
New oral small molecules are moving through trials to offer alternatives to injectable biologics for skin conditions.
Updated on Oct. 2, 2026 in Asthma
Live Poll
Would you prefer oral medication over injectable treatments for skin conditions?
Researchers are advancing oral TYK2 inhibitors and small molecules to treat atopic dermatitis for patients with needle aversion. These therapies aim to expand treatment options beyond the current reliance on injectable biologics.
Why it matters
Many individuals living with atopic dermatitis avoid necessary care due to needle aversion, driving the demand for effective oral alternatives. Expanding the range of administration methods is a key priority in dermatological care.
Thirteen biologics have been approved for psoriasis over the last two decades, with research now shifting toward evaluating novel oral TYK2 inhibitors and interleukin 2 receptor complex agents like rezpegaldesleukin in clinical trial cohorts.
The players
Leon Kircik
A researcher based in Louisville who investigates new dermatological therapies and receives funding from Enveda Biosciences.
The details
Oral small molecules are being engineered to inhibit specific signaling pathways, such as the TYK2 enzyme, to reduce the inflammation associated with dermatitis without requiring injections. By targeting these intracellular mechanisms, researchers hope to provide clinical outcomes comparable to injectable biologics while improving patient adherence for those who struggle with needle-based treatments.
Timeline
Psoriasis biologic development began two decades ago.
New data on TYK2 inhibitors is expected at the EADV congress in October 2026.
Health Landscape
The dermatological field is evolving from a heavy reliance on injectable biologics, established over the last two decades, toward more diverse oral small-molecule options. This shift aims to modernize treatment access by providing alternatives for patients who cannot or prefer not to use injections.
If you struggle with needle aversion in the management of chronic skin conditions, discuss emerging oral treatment options with your dermatologist to see if they align with your care plan. Understanding that newer, non-injectable pathways are in development can help you have a more informed conversation about your long-term management strategy.
The takeaway
The field of dermatology is actively working to diversify how we deliver medication to better support patient preferences and treatment adherence. Talk to your healthcare provider about how evolving research into oral therapies may impact your long-term skin health management.
What happens next
New data regarding TYK2 inhibitors is expected to be released at the EADV congress in Vienna in October 2026.
Further reading
Learn more about the latest innovations in Asthma and related inflammatory condition management.
Source note: This article includes information reported by Hcplive.
Live Poll
Would you prefer oral medication over injectable treatments for skin conditions?
